XQXinyuan Qiao

Xinyuan Qiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xinyuan Qiao has a total of 156 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A High-Potency Bovine Consensus Interferon Delivered by an Oral Lactococcus lactis System Exhibits Antiviral Activity Against VSV and BEV

    by Hongzhe Zhao, Rongyan Li, Yang Yang, Yingying Ma, Yanping Jiang, Jiaxuan Li, Wen Cui, Xinyuan Qiao

    Interferon-alpha (IFN-α) mediates innate antiviral immunity. Although it comprises multiple subtypes, their functional divergence and application potential remain incompletely characterized. In this study, we identified 13 BoIFN-α subtypes (A1–A13) in the bovine genome through bioinformatic analysis. Prokaryotic expression and functional comparison revealed substantial differences in antiviral activity among these subtypes (up to 77.7-fold), with BoIFN-A8 being the most potent. Based on these findings, we designed a novel consensus interferon, BoIFN-Acons, by multiple sequence alignment and successfully synthesized it. When expressed in E. coli, BoIFN-Acons exhibited superior antiviral potency (2.36 × 105 U/mg), which was 16.2-fold higher than that of the most active natural subtype. To establish a safe delivery system, we integrated the codon-optimized gene into a food-grade L. lactis expression platform and achieved efficient supernatant production. In vitro assays confirmed that the recombinant BoIFN-Acons effectively suppressed replication of Vesicular stomatitis virus (VSV) and Bovine enterovirus (BEV) and significantly upregulated interferon-stimulated genes (ISGs) such as Mx1 and OAS1. Furthermore, in vivo experiments demonstrated that oral administration of the engineered L. lactis strain alleviated virus-induced clinical symptoms, reduced viral loads in major tissues, and induced upregulation of immune-related genes in the spleen, showing significant prophylactic and therapeutic efficacy. Collectively, this study systematically elucidated the functional diversity of BoIFN-α subtypes and developed a highly active consensus interferon delivered via an oral lactic acid bacteria system, providing a new strategy for the eco-friendly control of animal viral diseases.


  • Open Access

    Prophylactic Administration of Engineered Bacillus subtilis Expressing Mucosal Repair Factors Alleviates Pullorum Disease in Chicks

    by Fei Teng, Yingying Ma, Xinrui Li, Rongyan Li, Yang Yang, Yue Yan, Hongzhe Zhao, Guiwei Li, Yanping Jiang, Jiaxuan Li, et al.

    Salmonella pullorum (S. pullorum) remains a major enteric pathogen in young chicks, causing high mortality and severe economic losses in poultry production. This study evaluated a prophylactic strategy using engineered Bacillus subtilis (B. subtilis) expressing gallus trefoil factor 2 (gTFF2) and epidermal growth factor (gEGF) to protect chicks against S. pullorum infection. In vitro, gEGF significantly promoted UMNSAH/DF-1 (DF-1) cell proliferation, whereas both gTFF2 and gEGF enhanced epithelial cell migration. In vivo, oral administration of recombinant B. subtilis significantly reduced mortality from 75.0% and 66.7% in the PBS and pHT43 groups to 50%, 33.3%, and 25.0% in the gTFF2, gEGF, and gTFF2+gEGF groups, respectively. Cecal colonization of S. pullorum was reduced by 2–4 log10 CFU/g, accompanied by improved average daily gain and immune organ indices. Treatment also significantly decreased serum IL-6 levels and increased TGF-β levels (p < 0.05), indicating attenuation of the inflammatory response. Histological analysis showed significantly increased villus height (0.94–1.58-fold) and villus height-to-crypt depth ratio (1.47–3.25-fold) compared with the infected controls, together with markedly alleviated hepatic and intestinal lesions. The combined administration of gTFF2- and gEGF-expressing strains consistently exhibited the greatest protective efficacy. Collectively, these findings demonstrate that engineered probiotic-mediated delivery of mucosal repair factors represents a promising antibiotic-alternative strategy for preventing pullorum disease and improving intestinal health in poultry production.

  • Open Access

    Lactobacillus casei bacterial ghost-based DNA vaccine enhances the immune protection effect by stimulating macrophages to regulate intestinal mucosal immunity

    by Yuxin Wei, Xiaoli Yu, Xiayu Zhang, Hongzhe Zhao, Fei Teng, Guiwei Li, Wei Wu, Mingze Chen, Jiaxuan Li, Yanping Jiang, et al.

    Porcine rotavirus is a major threat to the swine industry, yet effective vaccines are still lacking. Lactobacillus casei bacterial ghosts ( L. casei BGs) as DNA vaccine delivery vehicles represent a promising approach, providing a safe and structurally intact platform that enhances antigen presentation and elicits intestinal mucosal immunity. To elucidate how L. casei BGs regulate macrophage function and amplify mucosal immune responses, we investigated the response of macrophages and the intestinal mucosal immune system to an L. casei BG-based DNA vaccine encoding VP7. Using genetically engineered L. casei BGs, we performed in vitro macrophage stimulation and in vivo oral/intramuscular immunization in murine models, assessing phagocytic efficiency, TLR/MyD88/NF-κB pathway activation, M1 polarization, antigen presentation, serum IgG, fecal IgA, T cell proliferation, intestinal viral load, virus neutralization, and intestinal histopathology. Compared with a naked DNA vaccine, the L. casei BG-based vaccine significantly enhanced phagocytosis and antigen presentation and promoted M1 polarization via the TLR/MyD88/NF-κB pathway. Furthermore, oral administration of the vaccine proved superior to intramuscular injection in inducing mucosal immunity, preserving intestinal villus integrity, and enhancing antiviral protection. Collectively, this study establishes L. casei BGs as an effective DNA vaccine delivery system that enhances immunogenicity by modulating macrophage function and activating mucosal immunity, and offers a promising strategy for the control of porcine rotavirus infection.

  • Open Access

    Correction: Distribution of Staphylococcus aureus drug resistance genes, biofilm formation and cell wall characteristics in dairy cattle from dairy farms in Northeast China

    by Wei Wu, Hongzhe Zhao, Shize Hao, Guiwei Li, Xihuai Xue, Jiaxuan Li, Wen Cui, Yanping Jiang, Yingying Ma, Xinyuan Qiao

  • Untargeted metabolomics reveals bovine viral diarrhea virus infection reprogram host nucleotide and amino acid metabolism in MDBK Cells

    by Ting Xiao, Sen Gao, Xiayu Zhang, Fei Teng, Yuxin Wei, Wei Wu, Chenyu Zheng, Xinyuan Qiao, Wenlong Zhang, Yingying Ma

  • Phage therapy: A novel strategy to combat drug-resistant Salmonella Pullorum infection in chickens

    by Hongzhe Zhao, Shilong You, Jiahao Fu, Xiaoyu Xiong, Yingying Ma, Xiaona Wang, Rongyan Li, Fei Teng, Mingze Chen, Wei Wu, et al.

  • Open Access

    Biological functional identification of holins from Salmonella pullorum phages and their therapeutic efficacy against pullorum disease in chickens

    by Huyang Zhao, Wei Wu, Hongzhe Zhao, Chenyu Zheng, Fei Teng, Mingze Chen, Jiaxuan Li, Yanping Jiang, Wen Cui, Yingying Ma, et al.


  • Open Access

    Distribution of Staphylococcus aureus drug resistance genes, biofilm formation and cell wall characteristics in dairy cattle from dairy farms in Northeast China

    by Wei Wu, Hongzhe Zhao, Shize Hao, Guiwei Li, Xihuai Xue, Jiaxuan Li, Wen Cui, Yanping Jiang, Yingying Ma, Xinyuan Qiao

    The spread of drug-resistant Staphylococcus aureus(S.aureus) in cattle herds not only threatens livestock production but also becomes an important route fo


  • Open Access

    Biological function identification of phage holin Hol-4086 and treatment of Staphylococcus aureus infection

    by Chenyu Zheng, Yaxin Di, Yingchun Wang, Huyang Zhao, Ruichong Wang, Guiwei Li, Xiaona Wang, Zhifu San, Yanping Jiang, Wen Cui, et al.

    The treatment of infections caused by drug-resistant Staphylococcus aureus has become increasingly difficult. In this study, the complete genome of phage 4086-1 against S. aureus was sequenced and shown to be 17,960 bp in size, with a GC content of 29.14%. Phylogenetic analysis demonstrated that phage 4086-1 exhibited a close relationship with the Staphylococcus phages SLPW, JPL-50, and LSA2366. BLAST analysis indicated that ORF12 of phage 4086-1 (termed Hol-4086) shares high identity with other reported phage-associated holins. Hol-4086 consists of 140 amino acids and exhibits high sequence identity with some members of the phage_holin_4_1 superfamily (18–125 amino acids). Hol-4086 was then expressed in Escherichia coli and detected using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting. The results of a spot test demonstrated that Hol-4086 had substantial bacteriostatic effects on the host bacteria. S. aureus cells were exposed to Hol-4086 and observed using transmission electron microscopy and scanning electron microscopy. Bacterial cells treated with Hol-4086 showed ultrastructural and morphological changes. The detection of biofilm activity showed that Hol-4086 effectively inhibited and removed S. aureus biofilms. In vivo, treatment with Hol-4086 significantly reduced the number of bacteria, relieved inflammatory responses, and alleviated pathological changes in the organs of infected mice 48 h after treatment. These results demonstrate that Hol-4086 exhibits promising antibacterial potential as an alternative therapy for the treatment of infections caused by S. aureus.


  • Open Access

    Inhibitory Effects of Bovine Lactoferricin-Lactoferrampin on Senecavirus A and Foot-and-Mouth Disease Virus with Recombinant Lactobacillus Oral Treatment in Mice

    by Wenyue Zhao, Senhao Zhang, Ling Sui, Xiaona Wang, Jiaxuan Li, Wen Cui, Yanping Jiang, Xinyuan Qiao, Lijie Tang

    Foot-and-mouth disease virus (FMDV) and Senecavirus A (SVA) have similar pathogenic characteristics, and both are important pathogens that harm the livestock industry. Studies have shown that lactoferrin peptides can inhibit the replication of various viruses and enhance the body’s immune functions. Based on this, in the present study, we aimed to investigate the effects of bovine lactoferricin-lactoferrampin (LFCA) on replicating FMDV and SVA and to analyze its role in the cellular antioxidant response caused by viral infection; in addition, we fed mice with constructed recombinant Lactobacillus reuteri expressing LFCA. Treatment with LFCA at different stages significantly inhibited the replication of both SVA and FMDV. Pretreatment before SVA infection achieved an inhibition rate of up to 94.9%, while treatment during the FMDV replication stage achieved an inhibition rate of 74.3%. After infection with either virus, intracellular ROS and MDA levels were significantly reduced, as was GSH-Px activity. However, SOD activity showed no significant difference, compared with the virus-exposed group, and remained at a high level, suggesting an increased cellular antioxidant capacity. LFCA treatment significantly increased the transcription levels of the Nrf2, Ho-1, and Nqo1 genes. In mouse experiments, the LFCA-treated group showed significantly lower viral loads in lung and intestinal tissues, compared with the SVA infection group, validating LFCA’s protective effect against SVA infection. These findings demonstrate the potential of LFCA as an antiviral drug.